This site is intended for Healthcare Professionals only.

Haleon to close Maidenhead manufacturing site affecting 435 jobs


Share post:

Despite the closure, Haleon will retain its presence in the UK with corporate offices in Weybridge and London

Haleon, the consumer healthcare giant behind brands like Sensodyne toothpaste and Advil painkillers, has announced plans to shut down its Maidenhead manufacturing site in the UK.

This decision will impact 435 employees and comes as part of a broader strategic realignment of the company’s global manufacturing operations according to BBC.

The Maidenhead facility, which has been in operation for years, manufactures some of Haleon’s most popular oral health products, including Sensodyne and Parodontax.

However, following a comprehensive review of its manufacturing capabilities, the company has concluded that the site is no longer economically viable.

In a statement issued by a spokesperson for Haleon, they stated, “Following a strategic review of our global manufacturing capabilities, we have determined that our Maidenhead site is no longer a viable option for the manufacture of our products.”

“We have therefore taken the difficult decision to begin a phased closure of the site over a two-year period, subject to consultation.”

“This decision was not taken lightly, and our priority is to ensure that the people impacted are supported through this process.”

The closure of the site is set to occur over a phased two-year period, with consultations already underway to support affected employees through this challenging transition.

Despite the closure, Haleon remains committed to its presence in the UK, retaining corporate offices in Weybridge, Surrey, and London and some production is set to be transferred to Haelon‘s site in Slovakia.

Additionally, the company plans to invest £130 million in a new research and development facility in Weybridge, signaling its continued commitment to innovation and growth in the region.


Please enter your comment!
Please enter your name here

Current Issue June 2024

Related articles

Multiple sclerosis: England approves new jab that cuts hospital treatment time by 90%

In addition to significantly reducing treatment time for patients, the new multiple sclerosis injection could also save time...

NHS GP Patient survey2024 highlights positive pharmacy service experiences

According to the NHS survey, 49.7 per cent patients contacted a pharmacy via phone, practice websites (47.9 per...

NHS performance data highlights urgent need for government action

Commenting on the publication of the NHS monthly performance statistics Tim Gardner, Assistant Director of Policy at the...

Wes Streeting announces independent investigation into the state of NHS

Streeting stated that the NHS is "broken" and that this investigation will reveal "hard truths  The new health secretary,...